JP2024503235A5 - - Google Patents
Info
- Publication number
- JP2024503235A5 JP2024503235A5 JP2023537491A JP2023537491A JP2024503235A5 JP 2024503235 A5 JP2024503235 A5 JP 2024503235A5 JP 2023537491 A JP2023537491 A JP 2023537491A JP 2023537491 A JP2023537491 A JP 2023537491A JP 2024503235 A5 JP2024503235 A5 JP 2024503235A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- ppm
- crystal according
- values
- cukα radiation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063130530P | 2020-12-24 | 2020-12-24 | |
| US63/130,530 | 2020-12-24 | ||
| PCT/IB2021/062082 WO2022137106A1 (en) | 2020-12-24 | 2021-12-21 | Solid forms of a cdk2 inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024503235A JP2024503235A (ja) | 2024-01-25 |
| JP2024503235A5 true JP2024503235A5 (https=) | 2024-11-28 |
Family
ID=79283019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023537491A Pending JP2024503235A (ja) | 2020-12-24 | 2021-12-21 | Ｃｄｋ２阻害剤の固体形態 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240076287A1 (https=) |
| EP (1) | EP4267563A1 (https=) |
| JP (1) | JP2024503235A (https=) |
| KR (1) | KR20230122100A (https=) |
| CN (1) | CN116723837A (https=) |
| AU (1) | AU2021404974B2 (https=) |
| CA (1) | CA3206153A1 (https=) |
| MX (1) | MX2023007699A (https=) |
| TW (1) | TWI823213B (https=) |
| WO (1) | WO2022137106A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| US20250127759A1 (en) * | 2021-12-02 | 2025-04-24 | Pfizer Inc. | Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer |
| US20250195475A1 (en) * | 2022-01-27 | 2025-06-19 | InventisBio Co., Ltd. | Cdk2 inhibitor and preparation method and use thereof |
| WO2024046443A1 (en) * | 2022-09-01 | 2024-03-07 | Nutshell Biotech (Shanghai) Co., Ltd. | Macrocyclic compounds as selective cdk inhibitors |
| WO2025191482A1 (en) | 2024-03-15 | 2025-09-18 | Pfizer Inc. | Synthesis of (1h-pyrazol-5-yl)cyclopentyl carbamate compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
| IL284589B2 (en) | 2019-01-31 | 2025-10-01 | Pfizer | 3–Carbonylamino–5–cyclopentyl–h1–pyrazole compounds with cdk2 inhibitory activity |
-
2021
- 2021-12-21 WO PCT/IB2021/062082 patent/WO2022137106A1/en not_active Ceased
- 2021-12-21 US US18/268,959 patent/US20240076287A1/en active Pending
- 2021-12-21 KR KR1020237024476A patent/KR20230122100A/ko active Pending
- 2021-12-21 CN CN202180086069.9A patent/CN116723837A/zh active Pending
- 2021-12-21 MX MX2023007699A patent/MX2023007699A/es unknown
- 2021-12-21 CA CA3206153A patent/CA3206153A1/en active Pending
- 2021-12-21 AU AU2021404974A patent/AU2021404974B2/en active Active
- 2021-12-21 EP EP21839682.8A patent/EP4267563A1/en active Pending
- 2021-12-21 JP JP2023537491A patent/JP2024503235A/ja active Pending
- 2021-12-23 TW TW110148386A patent/TWI823213B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024503235A5 (https=) | ||
| JP2022049005A5 (https=) | ||
| JP2022186995A5 (https=) | ||
| FI4214202T3 (fi) | Cdk4-estäjän kiinteät muodot | |
| JP2016528179A5 (https=) | ||
| HRP20100166T1 (hr) | Postupak za pripremu 2-aminotiazol-5-aromatičnih karboksamida kao inhibitora kinaze | |
| JP2014527042A5 (https=) | ||
| RU2697521C2 (ru) | Кристаллы азабициклического соединения | |
| CN107406455B (zh) | 3,5-二取代的苯炔基化合物晶体 | |
| JP2007521340A5 (https=) | ||
| JP2006528973A5 (https=) | ||
| JP2023542093A5 (https=) | ||
| HRP20171895T1 (hr) | Hemisulfatna sol 5,10-metilen-(6r)-tetrahidrofolne kiseline | |
| JP2016528242A5 (https=) | ||
| JP2018531280A5 (https=) | ||
| JP2020536893A5 (https=) | ||
| WO2017136739A1 (en) | Glucose conjugates of triptolide, analogs and uses thereof | |
| JP2024037713A5 (https=) | ||
| JP2015516425A5 (https=) | ||
| CN107325096B (zh) | 一种阿维巴坦单钠盐的结晶 | |
| JP2022535850A5 (https=) | ||
| JP6676626B2 (ja) | アシルチオウレア化合物のメシル酸塩の結晶及びその製造方法 | |
| JP2022511495A5 (https=) | ||
| CN111630045A (zh) | 喹啉衍生物的结晶 | |
| HRP20240211T1 (hr) | Novi kristalni oblici tienopirimidina kao mcl-1 inhibitora |